This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Markets Up on Strength in Resorts, Airline Bookings
by Mark Vickery
As stimulus checks hit bank accounts across the nation and more Americans get their Covid-19 vaccine shots, pent-up demand in Travel & Leisure saw some big gains in select stocks today.
Roche (RHHBY) & Gilead's Drug Combo Study for COVID-19 Fails
by Zacks Equity Research
Roche's (RHHBY) Actemra in combination with Gilead's (GILD) Veklury did not meet the primary endpoint of improved time to hospital discharge for patients with severe COVID-19 pneumonia.
Vir Biotech (VIR)/Glaxo COVID-19 Drug Cuts Hospitalization Risk
by Zacks Equity Research
Vir Biotechnology (VIR) and partner Glaxo's, antibody candidate, VIR-7831, reduces hospitalization and risk of death in early treatment of adult patients with COVID-19.
Pharma Stock Roundup: EU Nod for J&J COVID-19 Vaccine, Updates From LLY, GSK, MRK
by Kinjel Shah
Europe clears J&J's (JNJ) COVID-19 vaccine. Eli Lilly (LLY), Merck (MRK) and Glaxo (GSK) give update on their COVID-19 antibody/antiviral candidates.
Lilly (LLY) Outperforms Industry Year to Date: Here's Why
by Zacks Equity Research
Lilly's (LLY) shares are up this year mainly due to positive developments related to its antibodies to treat COVID-19 and pipeline.
Novartis' (NVS) NSCLC Drug Fails to Meet Primary Endpoint
by Zacks Equity Research
Novartis (NVS) pipeline candidate, canakinumab, fails to meet the primary endpoint in lung cancer study.
The Zacks Analyst Blog Highlights: Eli Lilly, McDonald's, TOTAL, American Express and Southern Copper
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, McDonald's, TOTAL, American Express and Southern Copper
Top Research Reports for Eli Lilly, McDonald's & TOTAL
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly (LLY), McDonald's (MCD), and TOTAL SE (TOT).
Merck's (MRK) COVID-19 Drug Shows Promise in Mid-Stage Study
by Zacks Equity Research
Merck (MRK) announces encouraging preliminary data from a mid-stage study evaluating its oral COVID-19 antiviral candidate, molnupiravir, evaluating it in non-hospitalized adults with symptomatic COVID-19.
Lilly (LLY) COVID-19 Antibody Bamlanivimab Gets CHMP Nod
by Zacks Equity Research
CHMP recommends approval of Eli Lilly's (LLY) COVID-19 antibody bamlanivimab, alone and in combination with etesevimab in Europe.
Eli Lilly (LLY) Stock Moves -0.72%: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed the most recent trading day at $200.54, moving -0.72% from the previous trading session.
Biotech Stock Roundup: REGN, VIR's COVID-19 Updates, KMPH's Drug Approval & More
by Zacks Equity Research
The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Vir (VIR) and KemPharm, Inc. (KMPH).
Biohaven (BHVN) Q4 Earnings Miss, Nurtec Uptake Promising
by Zacks Equity Research
Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, continues to demonstrate strong launch uptake.
Why Is Lilly (LLY) Down 2.5% Since Last Earnings Report?
by Zacks Equity Research
Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Eli Lilly (LLY) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed at $204.89 in the latest trading session, marking a +0.52% move from the prior day.
Radius' (RDUS) Q4 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Radius (RDUS) reports a wider loss but beats sales estimates in the fourth quarter.
Nektar (NKTR) Q4 Earnings and Revenues Top, Pipeline On Track
by Zacks Equity Research
Nektar (NKTR) reports encouraging fourth-quarter 2020 results. The company plans to initiate a new registrational study on its lead pipeline candidate, bempegaldesleukin, in 2021.
United Therapeutics (UTHR) Q4 Earnings Miss, Sales Beat
by Zacks Equity Research
United Therapeutics' (UTHR) fourth-quarter earnings miss estimates while sales beat the same. Higher sales of Orenitram, Remodulin and Tyvaso offset lower sales of Unituxin and Adcirca.
2 Large Cap Stocks to Buy for Income and Growth Amid Tech Volatility
by Benjamin Rains
Investors might want to add a few large cap names outside of the tech world that also provide income through solid dividend yields...
FDA Issues New Guidelines for COVID-19 Vaccines, Tests, Drugs
by Kinjel Shah
The FDA encourages companies to evaluate the impact of COVID-19 virus variants on the efficacy or performance of their COVID-19 vaccines, tests and medicines.
RedHill (RDHL) Doses First Patient in Phase II/III COVID-19 Study
by Zacks Equity Research
RedHill (RDHL) doses first patient in phase II/III study of orally-administered RHB-107 (upamostat), an investigational new drug for patients with symptomatic COVID-19 who do not require hospital care.
Pharma Stock Roundup: Coronavirus Vaccine Updates From PFE, AZN & JNJ
by Kinjel Shah
WHO authorizes emergency use of AstraZeneca's (AZN) COVID-19 vaccine. J&J (JNJ) seeks conditional approval for its COVID-19 vaccine in EU.
Nektar (NKTR) Teams Up With Merck for Head & Neck Cancer Study
by Zacks Equity Research
Nektar's (NKTR) shares up following a deal with Merck for a combination study of bempegaldesleukin with Keytruda for advanced head and neck cancer study.
3 Great Blue Chip Dividend Stocks to Buy Now with Dow at Records
by Benjamin Rains
Investors should always be on the lookout for ways to diversify and bolster their portfolios. One great place to start is with large cap stocks that pay solid dividends...
The Zacks Analyst Blog Highlights: AstraZeneca, Eli Lilly, Sanofi, GlaxoSmithKline and Novartis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AstraZeneca, Eli Lilly, Sanofi, GlaxoSmithKline and Novartis